← board
AYRWF
distress 4/10 · elevated risk$0.00-60%today-98% from 52w high
Revenue
$464M
Liquidity
$35M
Runway
—
Shares 1y
+277%
Price & events
-81.8% over 6M
CatalystRating changeDilutionFinancingdashed = today
-60.0%
1D
-66.7%
1W
-75.0%
1M
-66.7%
3M
-81.8%
6M
-98.0%
1Y
-99.8%
2Y
-100.0%
5Y
-100.0%
All
Overview
- Market Cap
- $435.04K
- Enterprise Value
- $350.60M
- Volume
- 1.40K
- 52 Week Range
- $0.00 – $0.21
- Total Shares
- 108.76M
- Float Shares
- 93.46M
- % Held by Insiders
- 9.75%
- % Held by Institutions
- 0.68%
- RVOL
- 0.01x
- Beta
- 1.01
Pipeline · 0 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| No pipeline trials tracked. | |||||
Catalyst news & presentations · 0
- No catalyst news yet.
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
Shares out: 108,759,747 · 0 offerings/1y · 0 PIPEs
- none
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- 2024-11-14Roth MKMBuy
Competitors
- none identified
Recent news
- none
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.